Research advances in the clinical effect of tenofovir alafenamide in treatment of chronic hepatitis B
10.3969/j.issn.1001-5256.2019.08.040
- VernacularTitle:富马酸丙酚替诺福韦治疗慢性乙型肝炎的研究现状
- Author:
Suna WANG
1
;
Jianqi LIAN
;
Zhansheng JIA
Author Information
1. Department of Infectious Diseases, Tangdu Hospital of Air Force Medical University, Xi’an 710038, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
tenofovir;
tenofovir alafenamide;
tenofovir disoproxil fumarate;
treatment outcome
- From:
Journal of Clinical Hepatology
2019;35(8):1828-1833
- CountryChina
- Language:Chinese
-
Abstract:
Tenofovir alafenamide (TAF) is a novel nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) infection. Compared with tenofovir disoproxil fumarate, TAF has better plasma stability and stronger liver-targeting ability and can significantly reduce the adverse events of renal injury and reduced bone mineral density. This article summarizes the research advances in the pharmacological characteristics, metabolic pathways, drug interactions, drug resistance, and renal safety of TAF and its role in patients with chronic HBV infection.
